Physician profile
Randy E Oliver
NPI 1245219443
$5,008.96
in general payments reported to CMS, 2019-2025
34 companies · $14.66 in 2025
The $14.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $555 · 2021: $768 · 2022: $803 · 2023: $1,057 · 2024: $925 · 2025: $14.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $994.14 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $755.24 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $551.47 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $432.83 | 2019-2024 | Jardiance, Tradjenta |
| Amgen INC. | $381.77 | 2019-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $259.89 | 2019-2024 | Spravato, Xarelto |
| Abbvie INC. | $231.03 | 2023-2024 | |
| Pfizer INC. | $161.56 | 2019-2025 | |
| Dexcom, INC. | $150.59 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $142.37 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $139.16 | 2019-2024 | |
| Abbott Laboratories | $96.50 | 2021-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $87.79 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $58.21 | 2022-2023 | |
| Exact Sciences Corporation | $56.48 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $54.83 | 2022 | |
| Mylan Specialty L.P. | $52.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $45.81 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.52 | 2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $32.18 | 2019 | |
| Sumitomo Pharma America, INC. | $31.34 | 2023-2024 | Gemtesa |
| Daiichi Sankyo INC. | $29.94 | 2019 | |
| Inari Medical, INC. | $26.10 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $22.38 | 2023 | Watchman Access System |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Radius Health, INC. | $19.17 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.76 | 2024 | Jynarque |
| Roche Diabetes Care, INC. | $18.66 | 2019 | |
| Medtronic USA, INC. | $17.98 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.19 | 2023 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $15.46 | 2023 | |
| Optinose US, INC. | $15.30 | 2024 | |
| Amarin Pharma, INC. | $15.15 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.85 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.